Development and Independent Validation of a Prognostic Gene Expression Signature Based on RB1, PTEN,and TP53in Metastatic Hormone-sensitive Prostate Cancer Patients

Autor: Jiménez, Natalia, Garcia de Herreros, Marta, Reig, Òscar, Marín-Aguilera, Mercedes, Aversa, Caterina, Ferrer-Mileo, Laura, García-Esteve, Samuel, Rodríguez-Carunchio, Leonardo, Trias, Isabel, Font, Albert, Rodriguez-Vida, Alejo, Ángel Climent, Miguel, Cros, Sara, Chirivella, Isabel, Domènech, Montserrat, Figols, Mariona, Carles, Joan, Suárez, Cristina, Herrero Rivera, Daniel, González-Billalabeitia, Enrique, Cívico, Claudia, Sala-González, Núria, Ruiz de Porras, Vicenç, Ribal, Maria J., Prat, Aleix, Mellado, Begoña
Zdroj: European Urology Oncology; 20240101, Issue: Preprints
Abstrakt: Low mRNA expression of two or more of the tumor suppressor genes (TSGs) RB1, PTEN, and TP53correlated with adverse outcomes in patients with metastatic hormone-sensitive prostate cancer. These results were validated independently in the CHAARTED trial dataset. No interaction was observed between TSG signature and treatment.
Databáze: Supplemental Index